Cartesian Therapeutics (RNAC) Cash & Equivalents (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Cash & Equivalents data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 99.06% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 99.06% decrease from a year earlier, with the FY2025 full-year figure at $125.1 million, down 41.14% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.7 million, down from $125.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for RNAC reached as high as $219.2 million in Q3 2024 and fell as low as $1.7 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $105.8 million across 5 years, with a median of $112.0 million in 2023.
• Across the five-year window, Cash & Equivalents soared 176.44% in 2024 and plunged 99.22% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $106.4 million in 2022, then slipped by 27.74% to $76.9 million in 2023, then surged by 176.44% to $212.6 million in 2024, then slumped by 41.14% to $125.1 million in 2025, then plunged by 98.64% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $1.7 million in Q1 2026, $125.1 million in Q4 2025, and $1.7 million in Q3 2025.